Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

Presentation

Recognizing Dermatomyositis Phenotypes: Cancer Risk, MDA5 Disease, and Early Diagnosis

Description

The talk focused on recognizing important dermatomyositis phenotypes early because delayed diagnosis can have serious consequences. In one case, a patient was misdiagnosed for months before classic dermatomyositis skin findings were recognized; during that delay, she was found to have rapidly progressive small cell lung cancer that had metastasized, underscoring the need for prompt cancer screening in adults with dermatomyositis. The speaker highlighted cancer red flags including older age, cutaneous ulceration, dysphagia, refractory disease, and TIF1-gamma or NXP2 antibodies, but emphasized that screening should not wait for antibody results and should be comprehensive rather than limited to age- or sex-based routine screening. The IMACS guidelines were mentioned as a framework for risk stratification and enhanced screening in higher-risk patients. Treatment of cancer-associated dermatomyositis often aims to use the least immunosuppressive regimen that still controls symptoms, with IVIG and methotrexate commonly used alongside oncology care. The second major theme was MDA5 dermatomyositis, which can present with characteristic palmar papules, vasculopathic ulcers, and subtle skin findings even before antibody testing returns. Recognizing this phenotype is critical because it is strongly associated with interstitial lung disease, including rapidly progressive ILD with high mortality. The speaker stressed that clinicians should use the exam to identify MDA5 disease early, obtain chest imaging even without pulmonary symptoms, and remember that myositis panels are imperfect and should not delay diagnosis or treatment.

View more

Conclusions

Dermatomyositis in adults should prompt aggressive malignancy screening because it can be a paraneoplastic syndrome with serious consequences if missed.
Red-flag features such as advanced age, cutaneous ulceration, dysphagia, refractory disease, and TIF1-gamma or NXP2 antibodies increase suspicion for cancer-associated dermatomyositis.
Relying only on age- and sex-based routine screening can miss important occult cancers in dermatomyositis patients, so more comprehensive screening is needed.
The IMACS guidelines support risk-stratified cancer screening and recommend enhanced screening for patients with multiple high-risk features.
Cancer-associated dermatomyositis can improve when the underlying malignancy is treated and immunosuppression is chosen carefully to minimize interference with oncologic therapy.
The MDA5 cutaneous phenotype, especially palmar papules and vasculopathic lesions, can allow clinicians to recognize disease before antibody results return.
MDA5 dermatomyositis is strongly associated with interstitial lung disease, particularly rapidly progressive ILD, which carries high mortality.
Even patients without respiratory symptoms may have occult ILD, so chest imaging should be obtained when MDA5 disease is suspected.
Commercial myositis antibody panels have limited sensitivity, specificity, and standardization, so clinicians must diagnose and act on the clinical phenotype even when serologies are negative or pending.
Early recognition of dermatomyositis subtypes and prompt multidisciplinary management can substantially change outcomes, including survival and functional recovery.

Oldroyd et al. Nat Rev Rheumatol. 2023 Dec;19(12):805-817.
Moghadam-Kia et al. Arthritis Care & Research, 2016.